{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:40:18Z","timestamp":1787755218449,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40123-026-01457-3","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:30:48Z","timestamp":1785159048000},"page":"3071-3088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Dun Jack","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Riotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Fasolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Trivizki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Spooner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4159-3960","authenticated-orcid":false,"given":"Livia","family":"Faes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"2","key":"1457_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/ceo.13114","volume":"46","author":"KK Dansingani","year":"2018","unstructured":"Dansingani KK, Gal-Or O, Sadda SR, Yannuzzi LA, Freund KB. Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of \u201cexpanded spectra\u201d - a review. Clin Exp Ophthalmol. 2018;46(2):189\u2013200.","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"1457_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1\u20138.","journal-title":"Retina"},{"issue":"4","key":"1457_CR3","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41433-023-02764-w","volume":"38","author":"CMG Cheung","year":"2024","unstructured":"Cheung CMG. Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management. Eye (Lond). 2024;38(4):659\u201367.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1457_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen SJ, Kim JE, et al. Polypoidal choroidal vasculopathy: Consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV workgroup. Ophthalmology. 2021;128(3):443\u201352.","journal-title":"Ophthalmology"},{"issue":"5","key":"1457_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127(5):616\u201336.","journal-title":"Ophthalmology"},{"issue":"4","key":"1457_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/0002-9394(85)90682-8","volume":"100","author":"RM Stern","year":"1985","unstructured":"Stern RM, Zakov ZN, Zegarra H, Gutman FA. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. Am J Ophthalmol. 1985;100(4):560\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1457_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s41433-024-03253-4","volume":"39","author":"CMG Cheung","year":"2025","unstructured":"Cheung CMG, Dansingani KK, Koizumi H, Lai TYY, Sivaprasad S, Boon CJF, et al. Pachychoroid disease: review and update. Eye (Lond). 2025;39(5):819\u201334.","journal-title":"Eye (Lond)"},{"issue":"1","key":"1457_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41433-018-0225-x","volume":"33","author":"Y Yanagi","year":"2019","unstructured":"Yanagi Y, Foo VHX, Yoshida A. Asian age-related macular degeneration: from basic science research perspective. Eye (Lond). 2019;33(1):34\u201349.","journal-title":"Eye (Lond)"},{"issue":"6","key":"1457_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/ng.3546","volume":"48","author":"L Huang","year":"2016","unstructured":"Huang L, Zhang H, Cheng CY, Wen F, Tam POS, Zhao P, et al. A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy. Nat Genet. 2016;48(6):640\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"1457_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000774","volume":"36","author":"C Balaratnasingam","year":"2016","unstructured":"Balaratnasingam C, Lee WK, Koizumi H, Dansingani K, Inoue M, Freund KB. Polypoidal choroidal vasculopathy: a distinct disease or manifestation of many? Retina. 2016;36(1):1\u20138.","journal-title":"Retina"},{"key":"1457_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107\u201339.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1457_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease. Prog Retin Eye Res. 2010;29(1):19\u201329.","journal-title":"Prog Retin Eye Res"},{"issue":"16","key":"1457_CR13","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1038\/s41433-024-03221-y","volume":"38","author":"G De Salvo","year":"2024","unstructured":"De Salvo G, Thulasidharan S, Barbara R, Penwarden A, Aggarwal N, Frisina R. Real world treatment outcomes in polypoidal choroidal vasculopathy in a Caucasian population of British ethnicity. Eye (Lond). 2024;38(16):3072\u20136.","journal-title":"Eye (Lond)"},{"issue":"11","key":"1457_CR14","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206\u201313.","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"1457_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786\u201393.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1457_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000518235","volume":"245","author":"R Silva","year":"2022","unstructured":"Silva R, Arias L, Nunes S, Farinha C, Coimbra R, Marques JP, et al. Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the ATLANTIC study: a randomized clinical trial. Ophthalmologica. 2022;245(1):80\u201390.","journal-title":"Ophthalmologica"},{"issue":"9","key":"1457_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.oret.2025.02.030","volume":"9","author":"A Lazrak","year":"2025","unstructured":"Lazrak A, Bonnafous M, Jean-Charles A, Ouamrane K, Tabouillot A, Chaoui-Boudghane Y, et al. Exploring clinical features of polypoidal choroidal vasculopathy in Black patients: a cross-sectional study and a comprehensive review. Ophthalmol Retina. 2025;9(9):860\u20139.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"1457_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40942-017-0060-4","volume":"3","author":"T Alasil","year":"2017","unstructured":"Alasil T, Munoz N, Keane PA, Tufail A, Coady PA, Novais E, et al. Characteristics and racial variations of polypoidal choroidal vasculopathy in tertiary centers in the United States and United Kingdom. Int J Retina Vitreous. 2017;3(1):9.","journal-title":"Int J Retina Vitreous"},{"issue":"100118","key":"1457_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfop.2024.100118","volume":"7","author":"ON Okonkwo","year":"2024","unstructured":"Okonkwo ON, Hassan AO, Akanbi T, Agweye C, Onwuegbuna AA. Polypoidal choroidal vasculopathy versus neovascular age-related macular degeneration: a comparison of demographics, clinical presentation, and treatment outcomes in Nigerians. JFO Open Ophthalmol. 2024;7(100118):100118.","journal-title":"JFO Open Ophthalmol"},{"issue":"8","key":"1457_CR20","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1097\/IAE.0000000000000499","volume":"35","author":"CW Wong","year":"2015","unstructured":"Wong CW, Cheung CMG, Mathur R, Li X, Chan CM, Yeo I, et al. Three-year results of polypoidal choroidal vasculopathy treated with photodynamic therapy: retrospective study and systematic review. Retina. 2015;35(8):1577\u201393.","journal-title":"Retina"},{"issue":"7","key":"1457_CR21","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40123-024-00952-9","volume":"13","author":"MJ Sirks","year":"2024","unstructured":"Sirks MJ, Subhi Y, Rosenberg N, Hollak CEM, Boon CJF, Diederen RMH, et al. Perspectives and update on the global shortage of verteporfin (Visudyne\u00ae). Ophthalmol Ther. 2024;13(7):1821\u201331.","journal-title":"Ophthalmol Ther"},{"issue":"10326","key":"1457_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"8","key":"1457_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: Two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"key":"1457_CR24","unstructured":"Lai TYY, Chen SJ, Iida T, Koh AHC, Lee J, Lee WK, et al. Faricimab for polypoidal choroidal vasculopathy: 1-year results from the phase 3b\/4 SALWEEN trial. Paper presented at: 25th EURETINA Congress; 2025 Sep 4\u20137; Paris, France."},{"issue":"16","key":"1457_CR25","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1038\/s41433-025-03980-2","volume":"39","author":"J Cho","year":"2025","unstructured":"Cho J, Han HY, Park S, Kim JH, Cho HJ. One-year outcomes of faricimab versus aflibercept treatment for polypoidal choroidal vasculopathy: a comparative study. Eye (Lond). 2025;39(16):2893\u20138.","journal-title":"Eye (Lond)"},{"key":"1457_CR26","unstructured":"Tavares JF. ClinicalTrials.gov. 2025 [cited 2025 Dec 18]. Study to investigate the efficacy, safety and durability of faricimab in Caucasian patients with polypoidal choroidal vasculopathy (MONDEGO) (MONDEGO) NCT06709339. https:\/\/clinicaltrials.gov\/study\/NCT06709339#contacts-and-locations."},{"issue":"3","key":"1457_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/aos.16797","volume":"103","author":"A Arnold-Vangsted","year":"2025","unstructured":"Arnold-Vangsted A, Schou MG, Balaratnasingam C, Cehofski LJ, Chhablani J, van Dijk EHC, et al. Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis. Acta Ophthalmol. 2025;103(3):247\u201356.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"1457_CR28","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ajo.2014.08.025","volume":"158","author":"G De Salvo","year":"2014","unstructured":"De Salvo G, Vaz-Pereira S, Keane PA, Tufail A, Liew G. Sensitivity and specificity of spectral-domain optical coherence tomography in detecting idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol. 2014;158(6):1228-38.e1.","journal-title":"Am J Ophthalmol"},{"key":"1457_CR29","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.2147\/OPTH.S527787","volume":"19","author":"KCS Fong","year":"2025","unstructured":"Fong KCS, Wong WJJ, Wong HS, Ling KP, Fong SN, Shunmugam M. Switching to faricimab for polypoidal choroidal vasculopathy with real-world outcomes in refractory cases - the FAR-PEARL study report 1. Clin Ophthalmol. 2025;19:2475\u201385.","journal-title":"Clin Ophthalmol"},{"issue":"20","key":"1457_CR30","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","journal-title":"N Engl J Med"},{"issue":"14","key":"1457_CR31","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"key":"1457_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ajo.2023.12.011","volume":"261","author":"KYC Teo","year":"2024","unstructured":"Teo KYC, Zhao J, Ibrahim FI, Fenner B, Chakravarthy U, Cheung CMG. Features associated with vision in eyes with subfoveal fibrosis from neovascular age-related macular degeneration. Am J Ophthalmol. 2024;261:121\u201331.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1457_CR33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye. 2015;29(6):721\u201331.","journal-title":"Eye"},{"issue":"12","key":"1457_CR34","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.oret.2019.06.002","volume":"3","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Grewal DS, Teo KYC, Gan A, Mohla A, Chakravarthy U, et al. The evolution of fibrosis and atrophy and their relationship with visual outcomes in Asian persons with neovascular age-related macular degeneration. Ophthalmol Retina. 2019;3(12):1045\u201355.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"1457_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/IAE.0000000000003267","volume":"42","author":"KY Chong Teo","year":"2022","unstructured":"Chong Teo KY, Nguyen V, Gemmy Cheung CM, Arnold JJ, Chen FK, Barthelmes D, et al. The impact of disease activity on 5-year outcomes in patients undergoing treatment for neovascular age-related macular degeneration. Retina. 2022;42(1):95\u2013106.","journal-title":"Retina"},{"issue":"jan 24 1","key":"1457_CR36","doi-asserted-by":"publisher","first-page":"g1072","DOI":"10.1136\/bmj.g1072","volume":"348","author":"P Sedgwick","year":"2014","unstructured":"Sedgwick P. Retrospective cohort studies: advantages and disadvantages. BMJ. 2014;348(jan 24 1):g1072\u2013g1072.","journal-title":"BMJ"},{"issue":"8","key":"1457_CR37","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/IAE.0000000000001391","volume":"37","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Yanagi Y, Mohla A, Lee SY, Mathur R, Chan CM, et al. Characterization and differentiation of polypoidal choroidal vasculopathy using swept source optical coherence tomography angiography. Retina. 2017;37(8):1464\u201374.","journal-title":"Retina"},{"issue":"1","key":"1457_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35(1):1\u20139.","journal-title":"Retina"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01457-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01457-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:39:36Z","timestamp":1787751576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01457-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1457"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01457-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"2 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eleonora Riotto has nothing to disclose. Kimberly Spooner has nothing to disclose. Sandro Fasolo has nothing to disclose. Dun Jack Fu has received consulting fees and\/or research support from AbbVie, Allergan, Apellis, Boehringer Ingelheim, Galimedix, Google Health, the National Institute for Health and Care Research (NIHR), the Wellcome Trust, and Roche. Omer Trivizki has received consulting fees from Roche, AbbVie, Bayer, Galimedix, retina ai, and research support from PERCIEVE bio, RetinAI, Retinsight. Luke Nicholson has received funding and\/or fees from AbbVie, Alimera, Advanz, Astellas, Bayer, Boehringer Ingelheim, Biogen, Canon, Heidelberg, Optos, Roche. Sobha Sivaprasad has received funding and\/or fees from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, EyePoint Pharmaceuticals, Janssen Pharmaceuticals, Novo Nordisk, Optos, Ocular Therapeutix, Outlook Therapeutics, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics, Sandoz, and Sanofi. Livia Faes has received consulting fees and\/or research support from AbbVie, Allergan, Apellis, Bayer AG, Novartis, F. Hoffmann-La Roche AG, and Tavo. Livia Faes is Chief Medical Officer at medignition Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective observational study used routinely collected clinical data and was conducted in accordance with the Declaration of Helsinki. The study was registered with the Moorfields Eye Hospital NHS Foundation Trust Clinical Audit Department (registration number MEH1829) and was exempt from the requirement for institutional review board approval. Individual patient consent was not required because the study was retrospective, non-interventional, and used routinely collected clinical data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}